Metropolitan Life Insurance Company (MetLife)’s BioSpecifics Technologies Corp. BSTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,100
| Closed | -$111K | – | 2597 |
|
|
2020
Q3 | $111K | Hold |
2,100
| – | – | ﹤0.01% | 2156 |
|
|
2020
Q2 | $129K | Hold |
2,100
| – | – | ﹤0.01% | 2099 |
|
|
2020
Q1 | $119K | Hold |
2,100
| – | – | ﹤0.01% | 1919 |
|
|
2019
Q4 | $120K | Hold |
2,100
| – | – | ﹤0.01% | 2225 |
|
|
2019
Q3 | $112K | Hold |
2,100
| – | – | ﹤0.01% | 2238 |
|
|
2019
Q2 | $125K | Hold |
2,100
| – | – | ﹤0.01% | 2194 |
|
|
2019
Q1 | $131K | Hold |
2,100
| – | – | ﹤0.01% | 2160 |
|
|
2018
Q4 | $127K | Hold |
2,100
| – | – | ﹤0.01% | 2114 |
|
|
2018
Q3 | $123K | Buy |
+2,100
| New | +$107K | ﹤0.01% | 2333 |
|
|
2018
Q1 | – | Sell |
-2,256
| Closed | -$98K | – | 2509 |
|
|
2017
Q4 | $98K | Buy |
+2,256
| New | +$101K | ﹤0.01% | 2321 |
|
|
2017
Q3 | – | Sell |
-4,500
| Closed | -$223K | – | 2557 |
|
|
2017
Q2 | $223K | Hold |
4,500
| – | – | ﹤0.01% | 2268 |
|
|
2017
Q1 | $247K | Hold |
4,500
| – | – | ﹤0.01% | 2135 |
|
|
2016
Q4 | $251K | Hold |
4,500
| – | – | ﹤0.01% | 2203 |
|
|
2016
Q3 | $206K | Hold |
4,500
| – | – | ﹤0.01% | 2320 |
|
|
2016
Q2 | $180K | Buy |
4,500
+718
| +19% | +$26.3K | ﹤0.01% | 2393 |
|
|
2016
Q1 | $132K | Hold |
3,782
| – | – | ﹤0.01% | 2385 |
|
|
2015
Q4 | $163K | Hold |
3,782
| – | – | ﹤0.01% | 2387 |
|
|
2015
Q3 | $165K | Hold |
3,782
| – | – | ﹤0.01% | 2411 |
|
|
2015
Q2 | $195K | Buy |
+3,782
| New | +$161K | ﹤0.01% | 2419 |
|
Other funds holding BSTC
Metropolitan Life Insurance Company (MetLife)'s BSTC Position: Q4 2020 in Review
Metropolitan Life Insurance Company (MetLife) sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 2,100 shares — an estimated $111K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in BSTC in Q2 2015 and held it in 19 quarters. The position peaked at $251K in Q4 2016. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.
- Metropolitan Life Insurance Company (MetLife) reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 2,100 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $111K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in BioSpecifics Technologies Corp. in Q2 2015 and held it in 19 quarters.
- Metropolitan Life Insurance Company (MetLife)'s BioSpecifics Technologies Corp. position peaked at $251K in Q4 2016.
- 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2020, filed 16 Feb 2021.